ENLIVEN THERAPEUTICS, INC. Restricted Cash, Current
ENLIVEN THERAPEUTICS, INC. (ELVN) had Restricted Cash, Current of $0 as of 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:RestrictedCashCurrent · last filed 2026-03-03
- 2025-12-31: Restricted Cash, Current $0.00.
- 2025-09-30: Restricted Cash, Current $0.00.
- 2025-06-30: Restricted Cash, Current $0.00.
- 2025-03-31: Restricted Cash, Current $0.00.
| Period end | Restricted Cash, Current |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-03 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-12 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-13 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-14 |
| 2024-12-31 | $54.00K 10-K · filed 2026-03-03 |
| 2024-09-30 | $54.00K 10-Q · filed 2024-11-13 |
| 2024-06-30 | $54.00K 10-Q · filed 2024-08-13 |
| 2024-03-31 | $54.00K 10-Q · filed 2024-05-14 |
| 2023-12-31 | $54.00K 10-K · filed 2025-03-13 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |